These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31315253)

  • 1. Long-Lasting Mucosal and Systemic Immunity against Influenza A Virus Is Significantly Prolonged and Protective by Nasal Whole Influenza Immunization with Mucosal Adjuvant N3 and DNA-Plasmid Expressing Flagellin in Aging In- and Outbred Mice.
    Hinkula J; Nyström S; Devito C; Bråve A; Applequist SE
    Vaccines (Basel); 2019 Jul; 7(3):. PubMed ID: 31315253
    [No Abstract]   [Full Text] [Related]  

  • 2. DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant.
    Nyström S; Bråve A; Falkeborn T; Devito C; Rissiek B; Johansson DX; Schröder U; Uematsu S; Akira S; Hinkula J; Applequist SE
    Vaccines (Basel); 2013 Sep; 1(4):415-43. PubMed ID: 26344341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.
    Carroll TD; Jegaskanda S; Matzinger SR; Fritts L; McChesney MB; Kent SJ; Fairman J; Miller CJ
    J Infect Dis; 2018 Aug; 218(6):856-867. PubMed ID: 29701840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice.
    Qin T; Yin Y; Huang L; Yu Q; Yang Q
    Clin Vaccine Immunol; 2015 Apr; 22(4):421-9. PubMed ID: 25673304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
    Bungener L; Geeraedts F; Ter Veer W; Medema J; Wilschut J; Huckriede A
    Vaccine; 2008 May; 26(19):2350-9. PubMed ID: 18400340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
    Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
    Front Immunol; 2019; 10():646. PubMed ID: 30984200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced pulmonary immunization with aerosolized inactivated influenza vaccine containing delta inulin adjuvant.
    Murugappan S; Frijlink HW; Petrovsky N; Hinrichs WL
    Eur J Pharm Sci; 2015 Jan; 66():118-22. PubMed ID: 25459531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.
    Dong W; Bhide Y; Sicca F; Meijerhof T; Guilfoyle K; Engelhardt OG; Boon L; de Haan CAM; Carnell G; Temperton N; de Vries-Idema J; Kelvin D; Huckriede A
    Front Immunol; 2018; 9():2312. PubMed ID: 30356772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-Inactivated Influenza Virus Is a Potent Adjuvant for Influenza Peptides Containing CD8
    Soema PC; Rosendahl Huber SK; Willems GJ; Jacobi R; Hendriks M; Soethout E; Jiskoot W; de Jonge J; van Beek J; Kersten GFA; Amorij JP
    Front Immunol; 2018; 9():525. PubMed ID: 29593747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of the effects of virus inactivation methods on the induction of antibody- and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens.
    Astill J; Alkie T; Yitbarek A; Taha-Abdelaziz K; Bavananthasivam J; Nagy É; Petrik JJ; Sharif S
    Vaccine; 2018 Jun; 36(27):3908-3916. PubMed ID: 29853199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The type of adjuvant in whole inactivated influenza a virus vaccines impacts vaccine-associated enhanced respiratory disease.
    Souza CK; Rajão DS; Sandbulte MR; Lopes S; Lewis NS; Loving CL; Gauger PC; Vincent AL
    Vaccine; 2018 Oct; 36(41):6103-6110. PubMed ID: 30181048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice.
    Bodewes R; Kreijtz JH; Hillaire ML; Geelhoed-Mieras MM; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    J Gen Virol; 2010 Jul; 91(Pt 7):1743-53. PubMed ID: 20335492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective antibody responses against A(H1N1)pdm09 primed by infection and recalled by intranasal vaccination.
    Ikeda K; Ainai A; Hasegawa H
    Vaccine; 2015 Nov; 33(45):6066-9. PubMed ID: 26432916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
    Hagenaars N; Verheul RJ; Mooren I; de Jong PH; Mastrobattista E; Glansbeek HL; Heldens JG; van den Bosch H; Hennink WE; Jiskoot W
    J Control Release; 2009 Dec; 140(2):126-33. PubMed ID: 19712713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.